ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - A comparative study of two monoclonal antibodies

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 2, 2012, Pages 165-169

  Braun, M ^a   Goltz, D ^a   Adler, David ^a   Vogel, W ^a   Bohm D ^a   Scheble, V ^b   Sotlar, K ^c   Fend, F ^b   Tan, S H ^d   Dobi, A ^d   Kristiansen, G ^a   Wernert, N ^a   Perner, S ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

ERG immunohistochemistry; ERG protein expression; ERG rearrangement; gene fusions

Indexed keywords

MONOCLONAL ANTIBODY; PROTEOME; TRANSCRIPTION FACTOR ERG;

AMINO ACID SEQUENCE; ARTICLE; CANCER LOCALIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RABBIT; TISSUE MICROARRAY; TRANSCRIPTION FACTOR ERG GENE;

EID: 84862080503     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.67     Document Type: Article

References (29)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
2. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009; 56: 275-286.
3. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429-439.
4. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-3852.
5. Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bo TH, Stordrange L et al. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007; 30: 19-32.
6. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C et al TMPRSS2- ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions Neoplasia 2006 8 826-832
7. Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011; 58: 1028-1036.
8. Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 2010; 23: 1499-1506.
9. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S et al. ERGTMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011; 24: 1120-1127.
10. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24: 820-828.
11. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009; 22: 1176-1185.
12. Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56: 937-943.
13. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-8341.
14. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-3590.
15. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
16. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2009; 75: 762-767.
17. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J et al. TMPRSS2- ERG fusion prostate cancer: an early molecular vent associated with invasion. Am J Surg Pathol 2007; 31: 882-888.
18. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23: 1061-1067.
19. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13 228-237.
20. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011; 24: 1128-1138.
21. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-598.
22. He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with 'atypical glands suspicious for cancer'. Am J Surg Pathol 2011; 35: 608-614.
23. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14: 4719-4725.
24. Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011; 35: 432-441.
25. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008; 68: 8516-8524.
26. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 8347-8351.
27. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007; 26: 2667-2673.
28. Dobi A, Furusato B, Shaheduzzaman S, Chen Y, Vahey M, Nydam T et al. ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoter. Open Cancer J 2010; 3: 101-108.
29. Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ et al. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer 2010; 1: 197-208.